Last reviewed · How we verify

NCT06254677: WESTKiD

Western Sydney Kidney Injury Biopsy Study

Not yet recruiting Last updated 24 April 2024
What this trial tests

trial testing Retrospective review of histological features in Kidney Injury in 1,000 participants. Not yet recruiting.

Timeline
1 May 2024
Primary endpoint
1 January 2035
1 January 2040

Quick facts

Lead sponsorWestern Sydney Local Health District
StatusNot yet recruiting
Study typeOBSERVATIONAL
Enrollment1,000
Start date1 May 2024
Primary completion1 January 2035
Estimated completion1 January 2040

Drugs / interventions tested

Conditions studied

Sponsor

Western Sydney Local Health District — full company profile →

Who can join

Adults 18 to 80, any sex, with Kidney Injury. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The investigators aim to develop a clinically validated, histological acute tubular injury (ATI) scoring system to help improve diagnostic precision and predict clinical outcomes following ATI. To use an unbiased, data-driven approach, correlating pathological features (including digital pathology), key signatures using spatial technologies (transcriptomics or proteinomics) with relevant clinical outcomes. Spatial technologies (including spatial transcriptomics and spatial proteinomics) allow the use of 'precision pathology' to study the critical link between molecular characteristics to histological structure.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Kidney Injury

Currently open trials in the same condition.

Other Western Sydney Local Health District trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06254677.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing